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ABSTRACT
OBJECTIVE
To determine the distribution, and specifically the 
true 99th centile, of high sensitivity cardiac troponin I 
(hs-cTnI) for a whole hospital population by applying 
the hs-cTnI assay currently used routinely at a large 
teaching hospital.
DESIGN
Prospective, observational cohort study.
SETTING
University Hospital Southampton NHS Foundation 
Trust, Southampton, United Kingdom, between 29 
June 2017 and 24 August 2017.
PARTICIPANTS
20 000 consecutive inpatients and outpatients 
undergoing blood tests for any clinical reason. 
Hs-cTnI concentrations were measured in all study 
participants and nested for analysis except when the 
supervising doctor had requested hs-cTnI for clinical 
reasons.
MAIN OUTCOME MEASURES
Distribution of hs-cTnI concentrations of all study 
participants and specifically the 99th centile.
RESULTS
The 99th centile of hs-cTnI for the whole population 
was 296 ng/L compared with the manufacturer’s 
quoted level of 40 ng/L (currently used clinically 
as the upper limit of normal; ULN). Hs-cTnI 
concentrations were greater than 40 ng/L in one in 
20 (5.4%, n=1080) of the total population. After 
excluding participants diagnosed as having acute 
myocardial infarction (n=122) and those in whom 
hs-cTnI was requested for clinical reasons (n=1707), 
the 99th centile was 189 ng/L for the remainder 
(n=18 171). The 99th centile was 563 ng/L for 
inpatients (n=4759) and 65 ng/L for outpatients 
(n=9280). Patients from the emergency department 
(n=3706) had a 99th centile of 215 ng/L, with 6.07% 
(n=225) greater than the recommended ULN. 39.02% 
(n=48) of all patients from the critical care units 
(n=123) and 14.16% (n=67) of all medical inpatients 
had an hs-cTnI concentration greater than the 
recommended ULN.
CONCLUSIONS
Of 20 000 consecutive patients undergoing a blood 
test for any clinical reason at our hospital, one in 20 
had an hs-cTnI greater than the recommended ULN. 
These data highlight the need for clinical staff to 
interpret hs-cTnI concentrations carefully, particularly 
when applying the recommended ULN to diagnose 
acute myocardial infarction, in order to avoid 
misdiagnosis in the absence of an appropriate clinical 
presentation.
TRIAL REGISTRATION
Clinicaltrials.gov NCT03047785.
Introduction
The use of increasingly sensitive troponin assays for 
excluding or diagnosing acute myocardial infarction 
has become universal. A diagnosis of acute myocardial 
infarction is defined, in the context of an appropriate 
clinical presentation, by a rise or fall in cardiac 
troponin concentration, now the gold standard 
biomarker,1 2 with at least one value greater than the 
99th centile derived from a reference population of 
healthy individuals.3-5
Under most circumstances, the troponin assay is 
requested by frontline clinical staff to determine whether 
a patient is having a type 1 myocardial infarction 
caused by coronary plaque rupture or erosion. Robust 
evidence has shown symptomatic and prognostic 
benefit from applying early pharmacological and 
interventional treatment strategies in these patients. 
However, particularly with the advent of newer assays, 
this strategy has two potential challenges.
Firstly, raised cardiac troponin concentrations, 
particularly in patients not presenting with a typical 
history of cardiac pain, are often caused by myocardial 
injury or type 2 myocardial infarction.6 7 These 
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conditions, which are secondary to ischaemia caused 
by increased oxygen demand or decreased supply 
rather than a plaque erosion,8-10 are not well recognised 
when the troponin test is requested or the result 
interpreted. Correct diagnosis is important because 
most patients with type 2 myocardial infarction have 
not been shown to benefit from the same aggressive 
pharmacotherapy and invasive investigation and 
treatment that are offered as standard in patients 
with type 1 myocardial infarction.11 Some exceptions 
include spontaneous coronary dissection, coronary 
embolism, and coronary spasm.10 12 Misinterpretation 
may lead to inappropriate management, including 
prolonged antiplatelet therapy and invasive coronary 
angiography, with or without revascularisation.
Secondly, the assay specific 99th centile (upper 
limit of normal; ULN) is generally applied as a binary 
“rule in” or “rule out” threshold for acute myocardial 
infarction. Recent trial data confirm the veracity 
of using early cardiac troponin concentrations to 
confidently exclude a diagnosis of acute myocardial 
infarction13-16; however, the assumption that a 
concentration greater than the recommended threshold 
implies acute myocardial infarction (and in particular 
type 1 myocardial infarction) is often inappropriate.
Both of these potential issues may be compounded 
in clinical practice by the increasing sensitivity of 
the available assays that are able to detect troponin 
at much lower concentrations than previously.5 
Consequently, new highly sensitive cardiac troponin 
(hs-cTn) assays17-21 allow for rapid exclusion of acute 
myocardial infarction, and thereby enable patients 
to be discharged early from hospital. Furthermore, 
modern hs-cTn assays can detect troponin in more 
than 50% of the general population, with some assays 
able to detect troponin in everyone.22 The appropriate 
interpretation of raised hs-cTn, specifically in relation 
to the diagnosis of type 1 myocardial infarction, 
is therefore dependent on a clinical presentation 
consistent with this diagnosis, and, in particular, a 
history of cardiac-sounding chest pain, according to 
the guidelines.
The International Federation of Clinical Chemistry 
and Laboratory Medicine Task Force on Clinical 
Applications of Bio-Markers currently recommends 
that the 99th centile for any assay can be calculated 
using 300 “healthy” men and 300 “healthy” women.23 
However, several factors are known to affect an 
individual’s troponin,23 including age,24 sex,25 
glomerular filtration rate,26 left ventricular function,27 
and the presence of major inflammatory conditions.28 
Therefore, whether the clinically applied concept of a 
ULN for the hs-cTn assay is appropriate requires closer 
scrutiny, particularly when it has been derived from 
a limited number of healthy individuals. Importantly, 
the approaches to determining the recommended 99th 
centile are also variable.29-31
The objective of the CHARIOT study was to 
determine the true distribution of the highly sensitive 
cardiac troponin I (hs-cTnI) concentration, and 
more specifically the 99th centile, in a population of 
consecutive inpatients and outpatients in our hospital. 
Our hypothesis was that the true 99th centile of hs-cTnI 
in this population would differ from the manufacturer 
recommended ULN for this assay. This difference 
would highlight the potential for misinterpretation of 
a concentration greater than this threshold in routine 
clinical practice, particularly when making a diagnosis 
of acute myocardial infarction and especially type 1 
myocardial infarction.
Methods
Study population
This was a prospective, observational study of 20 000 
consecutive patients aged at least 18 years in whom 
a biochemistry blood test was requested for clinical 
reasons by their supervising doctor at our institution, 
University Hospital Southampton (United Kingdom). It 
was conducted between 29 June 2017 and 24 August 
2017. We included patients regardless of the setting in 
which the blood test was requested. Therefore, the study 
population consisted of outpatients and inpatients, 
attendees at the emergency department, elective and 
emergency admissions, and every specialty within the 
hospital. For each patient included in the study, only 
one troponin measurement was performed on the first 
biochemistry blood sample that became available 
during the study period. That patient was then 
excluded from further sampling so that a consecutive 
series of 20 000 different patients were included. 
During some of our analyses, we excluded patients in 
whom a troponin was requested for clinical reasons by 
the supervising doctor, and those in whom a diagnosis 
of acute myocardial infarction was made. This was 
determined by reviewing the electronic blood request 
forms submitted to the biochemistry department and 
by electronic discharge summaries.
Approvals
As part of the ethical committee process, we sought 
approval from the Confidentiality Advisory Group 
based on two unusual aspects of the methods. Firstly, 
patients did not know that an extra blood assay was 
being performed and consent was not sought or 
required. Secondly, except for patients who had an 
hs-cTnI test as part of their routine clinical care as 
requested by their supervising doctor, test results 
were nested and not revealed to either patients or 
their supervising clinical team; this was regardless of 
whether the level was greater than the recommended 
ULN.
Cardiac troponin I assay
The Beckman Coulter Access AccuTnI+3 assay 
(Brea, CA, USA) is used in routine clinical practice 
at our hospital. We applied this assay to measure 
hs-cTnI concentrations in the study population. The 
manufacturer’s recommended 99th centile (ULN) is 
40 ng/L, which is the level we use in routine clinical 
practice. The coefficient of variation of the assay is less 
than 10% at 40 ng/L; the limit of quantification (10% 
of the coefficient of variation) is 20 ng/L; the limit of 
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detection is 8 ng/L; and the limit of blank is 5 ng/L. For 
patients in whom troponin had not been requested for 
clinical reasons, we measured the hs-cTnI level using 
serum that was surplus to clinical need. An automated, 
bespoke system was installed in biochemistry to 
ensure that each patient was only included once in the 
study. We collected serum in serum separator tubes 
and stored it at room temperature for up to 24 hours 
before hs-cTnI levels were measured using the DxI800 
platform (Beckman Coulter). We performed quality 
control of the assay on a daily basis, which is routine 
in clinical practice.
Data collection
The baseline demographic data collected for the 
study were limited to those derived from electronic 
request forms for blood tests and, for inpatients, from 
electronic discharge summary codes. These data, 
together with the troponin levels and other study data, 
were saved on a bespoke database for later analysis.
Statistical analysis
We defined the 99th centile for the study population 
using a non-parametric procedure based on frequency 
tables. Statistical analyses were performed using IBM 
SPSS version 22.0 (Armonk, New York, NY, USA). 
We used Stata 14.0 (College Station, TX, USA) to 
perform multiple logistic regressions to identify factors 
associated with highly sensitive troponin levels greater 
than 40 ng/L. Variables in the model included age, male 
sex, serum sodium, estimated glomerular filtration rate, 
and location when the biochemistry test was requested.
Patient and public involvement
The British Cardiac Patients Association assisted 
the researchers in reviewing the study protocol, 
particularly with reference to the lack of consent from 
participants. As part of our study application, a letter 
of support for our methods from the chairman of the 
association was sent to the Health Research Authority 
and the Confidentiality Advisory Group.
Results
A total of 20 000 consecutive patients were included 
in the CHARIOT study between 29 June 2017 and 
24 August 2017. The median age was 61 (standard 
deviation 20) and 52.9% were women (n=10 580).
The 99th centile hs-cTnI concentration for the 
whole study population (n=20 000) was 296 ng/L, 
with one in 20 (5.4%; n=1080) patients having an hs-
cTnI concentration greater than the manufacturer’s 
recommended ULN (40 ng/L). When we excluded 
all patients diagnosed as having acute myocardial 
infarction on discharge from hospital or in whom an 
hs-cTnI test had been requested for clinical reasons, 
18 171 patients remained. The 99th centile in these 
patients was 189 ng/L, with 4.6% (n=836) having a 
level greater than 40 ng/L (fig 1). Table 1 presents the 
baseline characteristics.
Of the 1707 patients in whom hs-cTnI concentrations 
were requested by the clinical team, 73% (n=1246) 
had presented with chest pain; arrhythmia (n=52) 
and suspected blackouts (n=63) were the next most 
common reasons for the test.
Patient location
We stratified patients according to their location when 
the biochemistry test was requested. Specifically, the 
study included 9280 (51.1%) hospital outpatients in 
whom the observed 99th centile was 65 ng/L, with 
hs-cTnI concentrations greater than the recommended 
ULN in 2% (n=186). There were 4759 (26.2%) 
inpatients and the 99th centile for this group was 563 
ng/L; the hs-cTnI concentration was greater than the 
recommended ULN in 7.29% (n=347).
A total of 5708 patients had their blood sampling 
in the emergency department. Of this group, 1551 
(27.2%) had hs-cTnI concentrations requested by 
doctors in the department. The 99th centile for 
the remaining emergency department population 
(n=3706) was 215 ng/L, with 6.07% (n=225) 
having hs-cTnI concentrations greater than the 
recommended ULN. Of patients managed in the 
resuscitation room of the emergency department 
(n=426), 19.48% (n=83) had hs-cTnI concentrations 
greater than the ULN.
In the critical care setting (three intensive care units 
and two high dependency units; n=123), 39.02% 
(n=48) had hs-cTnI concentrations greater than the 
ULN. When we excluded all patients diagnosed as 
having myocardial infarction or who had an hs-cTnI 
test requested by the clinical team, 14.16% (n=67) 
of all medical inpatients (excluding those on cardiac 
wards) had an hs-cTnI concentration greater than the 
recommended ULN. For the medicine for older people 
wards, 20.8% (n=20) had an hs-cTnI concentration 
greater than the recommended ULN; for patients 
managed on the acute surgical unit, the corresponding 
figures were 4.62% (n=16), and for those on 
orthopaedic wards, 5.24% (n=13). In none of these 
patients was an acute myocardial infarction suspected 
or diagnosed (table 2; fig 2).
Age
There was an association between increasing age and 
distribution of troponin concentration. Supplementary 
tables 1 and 2, and figure 3 show centiles (25th, 50th, 
75th, and 99th) and proportion of patients with hs-
cTnI greater than the ULN according to age.
Sex
The 99th centiles for men and women were 373 and 236 
ng/L, respectively. A total of 6.6% (n=622) of men and 
4.38% (n=463) of women had hs-cTnI concentrations 
greater than the ULN. Significant differences were seen 
in mean hs-cTnI levels when comparing men with 
women (62 v 31 ng/L, P=0.021).
Multivariable analysis
When we excluded all patients who had been 
diagnosed with myocardial infarction or had hs-
cTnI tests requested by the clinical team (n=1829), a 
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multivariable analysis was undertaken. This analysis 
assessed the independent predictors of a patient 
having an hs-cTnI concentration greater than the 
recommended ULN (40 ng/L). Advancing age (odds 
ratio 1.03, 95% confidence interval 1.03 to 1.04, 
P<0.001), male sex (1.33, 1.14 to 1.54, P<0.001), and 
decreasing estimated glomerular filtration rate (0.98, 
0.97 to 0.98, P<0.001) were shown to be independent 
predictors. Furthermore, compared with the outpatient 
population, inpatient location was an independent 
predictor of hs-cTnI concentration greater than the ULN: 
emergency department (2.79, 2.26 to 3.43, P<0.001); 
resuscitation room (9.91, 7.3 to 13.46, P<0.001); 
critical care units (36.62, 23.86 to 56.2, P<0.001); 
cardiac wards (9.08, 6.44 to 12.81, P<0.001); acute 
surgical unit (2.52, 1.47 to 4.33, P<0.001); medical 
wards (4.74, 3.45 to 6.50, P<0.001); medicine for 
older people wards (3.70, 2.16 to 6.34, P<0.001); 
and orthopaedic wards (2.24, 1.23 to 4.05, P=0.008; 
table 3). Supplementary table 3 shows independent 
predictors for the full cohort (n=20 000).
Discussion
In this large study, we found that one in 20 consecutive 
inpatients and outpatients at a large UK hospital 
had a troponin level greater than the manufacturer 
recommended 99th centile (ULN) for the assay. We 
also showed that the true 99th centile varies according 
to the clinical setting, age and sex of the patient, and 
location when the biochemistry test was requested. 
Two per cent of outpatients and 39% of patients in 
critical care units had a hs-cTnI concentration greater 
than the recommended ULN.
These results have important clinical implications 
that are almost certainly relevant to the application 
of all modern hs-cTn assays. Firstly, they confirmed 
our hypothesis that the true 99th centile for a 
general hospital population is not consistent with 
the recommended ULN. Secondly, these data raise 
important questions about the applicability of the 
quoted ULN as an arbiter of type 1 acute myocardial 
infarction in patients who do not give a typical history 
consistent with this diagnosis. Previous evidence for 
using “negative” hs-cTnI levels to “rule out” acute 
myocardial infarction is clear cut and robust.14-16  32 
The Fourth Universal Definition3 recommends a 
diagnosis of acute myocardial infarction when there 
is clinical evidence of acute myocardial ischaemia 
and when an increase or decrease in cardiac troponin 
levels is detected. However, using the recommended 
ULN as a “rule in” test for acute myocardial infarction 
might not be appropriate in patients presenting with 
atypical symptoms and other comorbidities, such as 
in the emergency department or on acute medical and 
surgical wards. This approach could expose patients 
to inappropriate pharmacological and invasive 
treatments that have only been shown to be beneficial 
in true type 1 myocardial infarction populations.
These data demonstrate the importance of 
interpreting hs-cTnI results with caution in individual 
patients. The risk of potential systematic misdiagnosis 
of acute myocardial infarction is particularly shown by 
the observed 99th centile for hs-cTnI in our emergency 
department population (215 ng/L) and acute medical 
admissions (1459 ng/L). In addition, about 40% of 
patients in some clinical settings have hs-cTnI levels 
greater than the recommended ULN. It is important 
for frontline clinical staff to understand that using a 
single cutoff of hs-cTnI to diagnose acute myocardial 
infarction might be inappropriate and that the ULN 
of the assay depends on the setting and the clinical 
characteristics of patients. We would advocate that 
Table 1 | Baseline characteristics stratified by hs-cTnI levels (ng/L) less than or greater than ULN
Hs-cTnI <ULN (n=18 915) Hs-cTnI >ULN (n=1085) P value
Age (years) 57.4 74.2 <0.001
Male sex (No, %) 8796 (46.5) 622 (57.3) 0.005
eGFR(mL/min/1.73 m2) 79.1 59.6 <0.001
Sodium (mmol/L) 137.2 136 <0.001
Inpatients (No, %) 4540 (24.0) 405(37.3) <0.001
Outpatients (No, %) 9155(48.4) 189(17.4) <0.001
eGFR=estimated glomerular filtration rate; hs-cTnI=high sensitivity cardiac troponin I; ULN=upper limit of normal (40 ng/L).
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Fig 1 | Log distribution of high sensitivity cardiac troponin I (hs-cTnI) concentration 
in whole study population (n=20 000) and in final study population (n=18 171). 
ULN=manufacturer’s recommended upper limit of normal for hs-cTnI concentration  
(>40 ng/L)
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clinical staff are aware of the current guidelines for 
diagnosing acute myocardial infarction, which are not 
always adhered to, and also that they have a very clear 
indication for requesting the test.
Our analysis highlighted several factors that are 
associated with raised hs-cTnI levels according to 
the recommended threshold, including mode of 
presentation. We found that 7.29% of all inpatients 
in this study had a raised hs-cTnI concentration, 
including 6.07% of the emergency department 
population and 19.48% of patients admitted to the 
resuscitation room. It is more predictable that nearly 
40% of patients admitted to a critical care setting have 
an elevated concentration. In addition, the observed 
99th centile for hs-cTnI concentrations was 65 ng/L 
in outpatients, and 2% of these patients who attended 
the hospital only for an outpatient clinic appointment 
had a concentration greater than the recommended 
ULN. These results highlight the need for a review 
of the distribution of the hs-cTn assay in a hospital 
setting. Further research is also required to determine 
whether there is an association between absolute 
troponin concentration and cardiovascular outcome in 
such populations.
Other factors that were clearly associated with 
increasing hs-cTn concentrations were age and 
sex. Specifically, we found that almost double the 
proportion of patients in their 60s had hs-cTnI 
concentrations greater than the ULN compared with 
patients in their 50s. In addition, levels tended to be 
higher in men than in women. These observations lend 
weight to the concept that there should be age and sex 
specific recommendations for the ULN.
Comparison with other studies
Previous literature in this field has confirmed the 
use of the newer hs-cTn assays for early exclusion 
of acute myocardial infarction in a robust and safe 
manner.14-16 32 However, interpretation of a single 
hs-cTnI concentration above the supplied ULN as 
being an indicator of acute myocardial infarction, 
and, more specifically, type 1 myocardial infarction, 
by frontline clinical staff could lead to misdiagnosis 
and inappropriate investigations and treatment. Our 
data indicate that the prevalence of troponin levels 
above the supplied ULN in an important proportion of 
patients in whom there is no clinical suspicion of acute 
myocardial infarction should raise a cautionary note.
Our findings raise important and interesting 
questions about the potential implications of the 
observed distribution of hs-cTnI in the hospital 
population. Specifically, are the levels that we found 
in these patients, for whom the suspicion of acute 
myocardial infarction is low (for example, outpatients), 
actually abnormal? Do the levels indicate myocardial 
injury in their own right, and if so, are they associated 
with adverse outcome, perhaps as biomarkers for 
future cardiovascular risk? An accumulating body 
of evidence suggests that hs-cTn concentrations in 
populations of patients with stable chronic disease 
states, of cardiac and non-cardiac origin, are associated 
with risk of cardiovascular events.33-42 Notably, in the 
outpatient population it has been reported that hs-cTnI 
has been shown to be associated with an increased 
risk of vascular events and all cause mortality.43 44 It 
is conceivable that the raised hs-cTn concentrations 
in a patient with stable disease always indicates 
myocardial injury or unwellness: the so-called “never 
means nothing” hypothesis.45
Implications of this study
The results of the CHARIOT study have important 
clinical implications that might be relevant to the 
Table 2 | Distribution of hs-cTnI (ng/L) according to location when the biochemistry test was requested
Location No of patients Median (ng/L)
Interquartile 
range (ng/L)
Range 
(ng/L)
Proportion >ULN  
(% (No))
99th centile 
(ng/L)
Inpatients 4759 7 10 14 994 7.29 (347) 563
Outpatients 9280 5 8 3255 2.02 (187) 65
Emergency department 3706 7 9 6106 6.07 (225) 215
Resuscitation room 426 11 24 10 979 19.48 (83) 1839
Critical care units 123 25 115 13 086 39.02 (48) 12 097
Cardiac wards 269 14 28 14 994 21.56 (58) 3967
Acute surgical unit 346 6 9 2668 4.62 (16) 92
Medical wards 473 12 22 8807 14.16 (67) 1459
Medicine for older people 
wards 
96 20 27 3508 20.83 (20) —
Orthopaedic wards 248 8 9 402 5.24 (13) 184
Hs-cTnI=high sensitivity cardiac troponin I; ULN=upper limit of normal (40 ng/L).
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Fig 2 | Proportion of patients with high sensitivity cardiac troponin I concentration 
greater than manufacturer’s recommended upper limit of normal (ULN=40 ng/L), 
according to location when the biochemistry test was requested
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application of all modern hs-cTn assays. The notion of 
using a single binary value greater than the supplied 
ULN of any assay to diagnose whether a patient has 
had an acute myocardial infarction is flawed. This 
is highlighted by the observed 99th centile in the 
study population, which is over seven times higher 
than the ULN recommended by the manufacturer. 
Furthermore, the observed frequency of hs-cTnI 
greater than the recommended ULN, regardless of 
location, in patients in whom there was no clinical 
suspicion of acute myocardial infarction or myocardial 
injury raises concerns about using a 99th centile value 
from a “healthy population.” In particular, it might be 
inappropriate to apply the recommended 99th centile 
when managing patients who are typically older, have 
more comorbidities, a higher incidence of subclinical 
cardiac disease, and are in a worse physical condition 
than the healthy reference population.
The results of this study should highlight that 
although hs-cTnI can contribute to the diagnosis 
of acute myocardial infarction, frontline clinical 
staff should use this test in conjunction with other 
key factors, such as clinical history and other 
investigations.9 24 25 29 46-50 At present, using the 99th 
centile to help rule out a diagnosis of acute myocardial 
infarction is clear cut and is based on a “healthy” 
reference population. However, the recommended 
threshold and its application to patients presenting 
to hospital to rule in acute myocardial infarction 
is problematic, particularly when the degree of 
suspicion is low and other factors might contribute 
to the cardiac troponin concentration. Currently, the 
implications of detecting a hs-cTnI concentration 
above the supplied ULN, in terms of outcome and 
management, are unclear in patients in whom 
there is low clinical suspicion of acute myocardial 
infarction. A more considered approach to applying 
hs-cTnI concentrations would be to tailor the ULN 
according to the patient’s baseline characteristics and 
comorbidities. The feasibility of using this approach, 
however, has not been investigated. Further data 
about the potential association between hs-cTnI level 
and cardiovascular risk are required.
Limitations of this study
There were a number of limitations. This is an 
observational study of a large number of consecutive 
patients. Therefore, the level of detail about 
management and diagnoses can only be obtained 
from the best records available for each patient, 
which included electronic blood request or discharge 
summary data, and formalised coding records. In 
addition, we did not examine clinical outcomes 
because this was not part of our objective. We also 
used discharge codes in our analysis for diagnosing 
acute myocardial infarction, but these final diagnoses 
were not independently verified. Finally, this study 
looked at hs-cTnI concentrations in 20 000 patients 
based on a single sample for each patient; as a result, 
we could not differentiate between acute and chronic 
myocardial injury.
Conclusions
This study has shown that the 99th centile of 
high sensitivity troponin I concentration of the 
population in our hospital was substantially higher 
Table 3 | Independent predictors of hs-cTnI concentration greater than recommended ULN in final study population (n=18 171)
Variable
Predictors of manufacturer troponin  
ULN >40 ng/L 
Predictors of non-parametric troponin  
ULN >189 ng/L
Odds ratio (95% CI) P Odds ratio (95% CI) P
Age (per year increase) 1.03 (1.03 to 1.04) <0.001 1.03 (1.02 to 1.04) <0.001
Male sex 1.33 (1.14 to 1.54) <0.001 0.90 (0.66 to 123) 0.51
Sodium (per unit increase) 0.99 (0.97 to 1.01) 0.34 1.01 (0.97 to 1.04) 0.74
eGFR (per unit increase) 0.98 (0.97 to 0.98) <0.001 0.99 (0.98 to 1.00) 0.001
Inpatient location v outpatient
 Emergency department 2.79 (2.26 to 3.43) <0.001 3.46 (2.14 to 5.61) <0.001
 Resuscitation room 9.91 (7.3 to 13.46) <0.001 13.79 (7.67 to 24.77) <0.001
 Critical care units 36.62 (23.86 to 56.2) <0.001 99.27 (55.51 to 177.54) <0.001
 Cardiac wards 9.08 (6.44 to 12.81) <0.001 14.91 (7.91 to 28.11) <0.001
 Acute surgical unit 2.52 (1.47 to 4.33) 0.001 0.98 (0.13 to 7.21) 0.98
 Medical wards 4.74 (3.45 to 6.50) <0.001 5.80 (2.95 to 11.42) <0.001
 Medicine for older people wards 3.70 (2.16 to 6.34) <0.001 9.60 (4.00 to 23.00) <0.001
 Orthopaedic wards 2.24 (1.23 to 4.05) 0.008 2.15 (0.51 to 9.14) 0.30
eGFR=estimated glomerular filtration rate; hs-cTnI=high sensitivity cardiac troponin I; ULN=upper limit of normal (40 ng/L).
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Fig 3 | Upper limit of normal concentration of high sensitivity cardiac troponin I 
(ULN=40 ng/L) according to age of patients
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than the manufacturer’s recommended ULN used 
in clinical practice based on the 99th centile for a 
healthy population. Furthermore, the 99th centile 
for the hospital population varied depending on 
the clinical setting, age and sex of the patient, and 
location when the test was requested; however, in 
all groups, a proportion of the patients had hs-cTnI 
concentrations greater than the recommended ULN. 
The study observations highlight the need for clinical 
staff to interpret hs-cTnI concentrations carefully and 
systematically when making a diagnosis of acute 
myocardial infarction, particularly type 1 myocardial 
infarction.
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